Results for the substance crizotinib

Crizotinib is a medication used for the treatment of certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations, such as ALK (anaplastic lymphoma kinase) or ROS1. It acts as a tyrosine kinase inhibitor, blocking signals that promote cancer cell growth.

The medication is taken orally, usually twice daily, with the dose adjusted based on the patient's response and any adverse reactions. Common side effects include nausea, diarrhea, fatigue, and visual disturbances.

Crizotinib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or cardiac conditions.

This medication is an important option for patients with advanced NSCLC, helping to slow disease progression and improve quality of life.